Our knowledge of drug transporter interactions continues to evolve. Recently, it has been shown that compound-specific transporter […]
Read more...Our knowledge of drug transporter interactions continues to evolve. Recently, it has been shown that compound-specific transporter […]
Read more...Late stage failure of new therapies during clinical trials is a huge concern to the pharmaceutical industry […]
Read more...TAK-875, otherwise known as fasiglifam, is a GPR40 agonist that was developed for type 2 diabetes mellitus. […]
Read more...